Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility
Sign Up to like & getrecommendations! Published in 2023 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2023.0698
Abstract: Key Points Question Can the outcomes of pivotal trials conducted among patients with extensive-stage small cell lung cancer (ES-SCLC) be applied in a clinical practice setting? Findings In this cohort study of 207 patients with… read more here.
Keywords: eligibility; trial; stage small; patients extensive ... See more keywords
Burden of chemotherapy‐induced myelosuppression among patients with extensive‐stage small cell lung cancer: A retrospective study from community oncology practices
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5738
Abstract: Myelosuppression is a major dose‐limiting complication of chemotherapy for patients with extensive‐stage small cell lung cancer (ES‐SCLC). The objective was to describe the burden of myelosuppression, treatment patterns, and supportive care use among patients with… read more here.
Keywords: oncology; myelosuppression; patients extensive; extensive stage ... See more keywords
Durvalumab: A Review in Extensive-Stage SCLC
Sign Up to like & getrecommendations! Published in 2021 at "Targeted Oncology"
DOI: 10.1007/s11523-021-00843-0
Abstract: Durvalumab (IMFINZI®), a fully human monoclonal antibody against programmed cell death-ligand 1 (PD-L1), is approved for use in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small… read more here.
Keywords: chemotherapy; combination; durvalumab; extensive stage ... See more keywords
Treatment and outcome of 432 patients with extensive-stage small cell lung cancer in first, second and third line - Results from the prospective German TLK cohort study.
Sign Up to like & getrecommendations! Published in 2019 at "Lung cancer"
DOI: 10.1016/j.lungcan.2019.02.026
Abstract: OBJECTIVES Despite intensive research, the therapeutic options in extensive-stage small cell lung cancer (SCLC) are still limited. Data from routine clinical practice, so-called "real-world data", are centrally important to assess and improve the standard of… read more here.
Keywords: second third; third line; line; treatment ... See more keywords
Impact of thoracic radiation therapy after chemotherapy on survival in extensive‐stage small cell lung cancer: A propensity score‐matched analysis
Sign Up to like & getrecommendations! Published in 2019 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.13001
Abstract: The role of thoracic radiation therapy (TRT) after chemotherapy (CHT) in extensive‐stage small cell lung cancer (ES‐SCLC) has not been well defined. We investigated whether intensity‐modulated radiotherapy (IMRT) improves outcomes in ES‐SCLC after CHT compared… read more here.
Keywords: radiation therapy; stage small; thoracic radiation; extensive stage ... See more keywords
Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period
Sign Up to like & getrecommendations! Published in 2021 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14289
Abstract: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with a short replication time and a rapid growth rate. Prognostic factors for SCLC in clinical practice are scarce. Retrospective analysis of 8‐year extensive‐stage… read more here.
Keywords: cancer; cell lung; small cell; extensive stage ... See more keywords
Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide‐platinum‐atezolizumab treatment
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14697
Abstract: The phase III trial IMpower133 showed that platinum and etoposide plus atezolizumab was associated with improved overall survival (OS) and progression free‐survival (PFS) when compared to the placebo group in treatment‐naïve extensive stage (ES) small… read more here.
Keywords: cancer; stage small; small cell; treatment ... See more keywords
Clinical impact of first‐line PD‐1 or PD‐L1 inhibitors combined with chemotherapy in extensive‐stage small cell lung cancer patients: A real‐world multicenter propensity score‐matched study
Sign Up to like & getrecommendations! Published in 2023 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14874
Abstract: Our research aimed to evaluate the effectiveness of first‐line immune checkpoint inhibitors (ICIs) with etoposide and platinum (EP) for extensive‐stage small cell lung cancer (ES‐SCLC) and identify prognostic factors, as real‐world outcomes and the inconsistency… read more here.
Keywords: cancer; first line; stage small; small cell ... See more keywords
Efficacy and Safety of First-Line Immunotherapy in Combination with Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Oncology"
DOI: 10.1155/2020/2368164
Abstract: Background The prognosis of patients with extensive-stage small cell lung cancer (SCLC) is poor. Adding an immune checkpoint inhibitor (ICI) to chemotherapy may exert a synergistic effect and improve survival outcomes. However, for treatment-naive extensive-stage… read more here.
Keywords: chemotherapy; first line; extensive stage; immunotherapy ... See more keywords
Durvalumab Lengthens Survival in Extensive-Stage SCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2019-127
Abstract: In the phase III CASPIAN trial, the PD-L1 inhibitor durvalumab plus standard chemotherapy outperformed chemotherapy alone, extending median overall survival in patients with extensive-stage small cell lung cancer. read more here.
Keywords: durvalumab lengthens; extensive stage; durvalumab; survival extensive ... See more keywords
The Relation between Hemogram Parameters and Survival in Extensive-Stage Small Cell Lung Cancer
Sign Up to like & getrecommendations! Published in 2019 at "Oncology Research and Treatment"
DOI: 10.1159/000501595
Abstract: Purpose: To determine whether hemogram parameters have prognostic effects on survival in patients with extensive-stage small cell lung cancer (ED-SCLC). Methods: This retrospective analysis included 113ED-SCLC patients, who were followed in an oncology clinic. The… read more here.
Keywords: stage small; hemogram parameters; extensive stage; oncology ... See more keywords